THERAPEUTIC CLASS

Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant orALK-Positive Non–Small-Cell Lung Cancer With Brain Metastases

---

Patients with advanced EGFR-mutant or ALK-positive non–smallcell lung cancer (NSCLC) have a high cumulative risk (>70%) for developing brainmetastases (BrM) during the course of their disease. Recently, an update of the graded prognostic assessment (GPA) for patients with NSCLCandBrMhas established that molecular alterations in EGFR or ALK are an independent prognostic factor for betteroutcomes.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Fonkopac
Oncology
Carboplatin
Epirubicin

Specific Detail Info

JAMA Oncology

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment